Loading clinical trials...
Loading clinical trials...
Phase II Multi-centre Randomized Controlled Study of Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg
Conditions
Interventions
Gefitinib 500mg/Gefitinib 250mg
Locations
1
China
Cancer Center of Sun-Yat Sen University
Guangzhou, Guangdong, China
Start Date
May 1, 2009
Primary Completion Date
January 1, 2012
Completion Date
December 1, 2013
Last Updated
December 10, 2013
NCT06305754
NCT07190248
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Sun Yat-sen University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions